Skip to main content
Livermore
Livermore
ZHEN

Knoll Capital Management, LLC

SEC CIK
0001325083
Latest filing
Sep 9, 2026

The latest 13F from Knoll Capital Management, LLC covers Q2 2026 (filed Sep 9, 2026): 37 long positions worth $208.6M. The top 10 holdings make up 63.7% of the portfolio, and the largest is Biohaven Ltd. (BHVN) at 16.8%. Livermore has 23 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
1
Est. +$4.66M
Added
5
Est. +$8.60M
Reduced
0
Sold out
1
Est. −$135.0K

Top 5 holdings

Share of this quarter's portfolio value

  1. BHVNBiohaven Ltd.
    16.8%$35.0MHistory
  2. MGTXMeiraGTx Holdings plc
    8.1%$16.9MHistory
  3. PHYSSprott Physical Gold Trust
    5.6%$11.7MHistory
  4. ALDXAldeyra Therapeutics, Inc.
    5.6%$11.7MHistory
  5. OCULOcular Therapeutix, Inc
    5.4%$11.3MHistory

Share of portfolio

Top 5 holdings and the other 32 positions, by share of portfolio value

  1. BHVN16.8%
  2. MGTX8.1%
  3. PHYS5.6%
  4. ALDX5.6%
  5. OCUL5.4%
  6. Other 32 positions58.5%

Biggest buys

New and added positions, by estimated amount bought

  1. OCULOcular Therapeutix, Inc
    +$5.40MAddedHistory
  2. ABVXAbivax S.A.
    +$4.66MNewHistory
  3. ELTXElicio Therapeutics, Inc.
    +$2.27MAddedHistory
  4. NUVBNuvation Bio Inc.
    +$568.0KAddedHistory
  5. BHVNBiohaven Ltd.
    +$355.9KAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. BHVNBiohaven Ltd.
    +5.85 pp10.9% → 16.8%History
  2. OCULOcular Therapeutix, Inc
    +2.59 pp2.8% → 5.4%History
  3. ABVXAbivax S.A.
    +2.24 pp0.0% → 2.2%History
  4. NUVBNuvation Bio Inc.
    +0.78 pp3.6% → 4.4%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. CRDLCardiol Therapeutics Inc.
    −$135.0KSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. CRDLCardiol Therapeutics Inc.
    −0.07 pp0.1% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$208.6M
+$28.5M (+15.8%) vs. prior quarter
Positions
37
0 vs. prior quarter
Top 10 concentration
63.7%
Top 10 as share of value
Turnover
0.1%
Q2 2026, one quarter
Average holding period
11.9 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $218.0M (Q4 2025)

Q1 2021: $153.5MQ2 2021: $191.5MQ3 2021: $200.5MQ4 2021: $182.0MQ1 2022: $159.3MQ2 2022: $175.2MQ3 2022: $171.1MQ4 2022: $44.3MQ1 2023: $59.8MQ2 2023: $81.7MQ3 2023: $96.3MQ4 2023: $120.8MQ1 2024: $160.7MQ2 2024: $148.4MQ3 2024: $207.0MQ4 2024: $155.3MQ1 2025: $153.7MQ2 2025: $140.7MQ3 2025: $186.6MQ4 2025: $218.0MQ1 2026: $180.2MQ2 2026: $208.6M
Q1 2021Q2 2026
13F filings of Knoll Capital Management, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Sep 9, 2026Amended37$208.6MBHVNMGTXPHYSvs. Q1 2026SEC
Q1 2026May 15, 202637$180.2MBHVNPHYSRGLDvs. Q4 2025SEC
Q4 2025Feb 17, 202633$218.0MALDXBHVNNUVBvs. Q3 2025SEC
Q3 2025Nov 14, 202538$186.6MALDXBHVNGLDvs. Q2 2025SEC
Q2 2025Aug 14, 202538$140.7MALDXBHVNENTXvs. Q1 2025SEC
Q1 2025May 15, 202536$153.7MALDXBHVNENTXvs. Q4 2024SEC
Q4 2024Feb 18, 202535$155.3MBHVNALDXENTXvs. Q3 2024SEC
Q3 2024Nov 14, 202436$207.0MAPLTBHVNALDXvs. Q2 2024SEC
Q2 2024Aug 14, 202435$148.4MAPLTBHVNALDXvs. Q1 2024SEC
Q1 2024May 15, 202434$160.7MAPLTBHVNALDXvs. Q4 2023SEC
Q4 2023Feb 14, 202432$120.8MBHVNALDXAPLTvs. Q3 2023SEC
Q3 2023Nov 14, 202337$96.3MALDXAPLTBHVNvs. Q2 2023SEC
Q2 2023Aug 15, 202326$81.7MALDXBHVNAVDLvs. Q1 2023SEC
Q1 2023May 15, 202324$59.8MALDXBHVNVRNAvs. Q4 2022SEC
Q4 2022Feb 14, 202321$44.3MALDXBHVNALTvs. Q3 2022SEC
Q3 2022Nov 14, 202233$171.1MBHVNALDXENTXvs. Q2 2022SEC
Q2 2022Aug 15, 202241$175.2MBHVNALDXEIGRvs. Q1 2022SEC
Q1 2022May 16, 202241$159.3MBHVNENTXEIGRvs. Q4 2021SEC
Q4 2021Feb 14, 202238$182.0MBHVNAPLTENTXvs. Q3 2021SEC
Q3 2021Nov 15, 202140$200.5MBHVNAPLTENTXvs. Q2 2021SEC
Q2 2021Aug 16, 202142$191.5MBHVNAPLTENTXvs. Q1 2021SEC
Q1 2021Jun 14, 202139$153.5MBHVNAPLTCRBP–SEC

13D and 13G filings

Companies where Knoll Capital Management, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

1 company, largest stake first.

Companies where Knoll Capital Management, LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
ELTXElicio Therapeutics, Inc.13G/A5.30%1.21M shares+0.10 ppfrom 5.20%Feb 5, 20252 filingsJul 8, 2026SEC

Latest filings

9 filings on file made by Knoll Capital Management, LLC or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Knoll Capital Management, LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
ELTXElicio Therapeutics, Inc.Jul 8, 20262:18 PM ET13G/A5.30%1.21M shares+0.10 ppfrom 5.20%Jul 1, 2026SEC
ELTXElicio Therapeutics, Inc.Feb 5, 202511:10 AM ET13G5.20%630.9K sharesNewJan 30, 2025SEC
ENTXEntera Bio Ltd.Nov 20, 202413G/AOld format–––SEC
ENTXEntera Bio Ltd.Jan 16, 202413G/AOld format–––SEC
ALDXAldeyra Therapeutics, Inc.Oct 4, 202313GOld format–New–SEC
HOOKHOOKIPA Pharma Inc.Jun 20, 202313GOld format–New–SEC
APLTApplied Therapeutics, Inc.Jan 23, 202313GOld format–New–SEC
ENTXEntera Bio Ltd.Jun 14, 202113G/AOld format–––SEC
ENTXEntera Bio Ltd.Feb 16, 202113GOld format–New–SEC